Accurate Spike-in of Circulating Tumor Cells into Blood Samples is Essential for Reliable Analysis in Oncology ApplicationsBerlin, Germany, Lyon, France, and Seattle, WA, USA, June 22, 2020: SCIENION AG and RareCyte Inc. today announced that cellenONE® proved to be a most appropriate device for accurate single-cell dispensing of low numbers of model circulating tumor cells (CTCs) in oncology applications. RareCyte uses the versatile technology of SCIENION’s French subsidiary Cellenion for precise and reproducible dosing of a predefined number of targeted CTCs into blood samples.
RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue MultiplexingSEATTLE, Dec. 19, 2019 - RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M financing from new and existing investors. The funding will drive a global sales expansion for its instrument and consumables platform used in research and clinical markets. The $22M investment was led by HealthQuest Capital, with participation from 5AM Ventures and company founder, Ron Seubert.
This webinar describes how the RareCyte platform for CTC analysis was validated in the Clinical Diagnostics Lab (CAP accredited CLIA Lab) at Eli Lilly. Validation studies including analysis of accuracy and precision of CTC enumeration will be presented. As these results met the requirements of the Clinical Drug Study Team, the team at Lilly added the RareCyte platform to a global clinical trial for further evaluation in collaboration with a CRO. A short presentation on RareCyte CTC assays for enumeration, multi-biomarker analysis, and custom assay development capabilities will follow.Speakers:
Jeff Fill, MBA, MT(ASCP), Senior Director, Diagnostic and Experimental Pathology, Lilly Research Laboratories, Eli Lilly and Company
Arturo Ramirez, PhD, Director of Oncology, Biology R&D, RareCyte, Inc.
Wednesday, July 15, 2020 11:00 am
Eastern Daylight Time (New York, GMT-04:00)